To evaluate the long-term results of aortic valve replacement (AVR) and mitral valve replacement (MVR) with the Sorin Bicarbon prosthesis (SBP).Five hundred seven patients (306 men, 201 women), mean age 62 ± 10 years (range, 21-86 years), received an SBP between 1994 and 2000; AVR was performed in 344 (67\%) and MVR in 163 (33\%). The main concomitant procedure was coronary artery grafting in 79 patients (16\%). Follow-up was 99\% complete; mean follow-up was 12.7 ± 4.0 years with a cumulative duration of follow-up of 6475 patient-years in the entire group (4348 patient-years for AVR and 2124 patient-years for MVR).Hospital mortality was 2.7\% (AVR, 2.03\%; MVR, 4.3\%). There were 169 late deaths (AVR, 128; MVR, 41). Actuarial survival at 17 years is 49.7\% ± 5.3\% for AVR and 62.0\% ± 6.1\% for MVR. At the last follow-up, 310 survivors (199 AVR, 111 MVR) are in New York Heart Association functional class I or II. At 17 years, actuarial freedom from valve-related deaths, embolism, and bleeding is 89.8\% ± 4.8\%, 85.8\% ± 5.4\%, and 96.2\% ± 1.2\% after AVR, and 91.9\% ± 3.9\%, 96.3\% ± 1.8\%, 95.0\% ± 2.9\% after MVR. Reoperation was required in 5 patients with AVR (thrombosis in 4 and perivalvular leak in 1). Actuarial freedom from reoperation is 98.1\% ± 0.8\% after AVR and 100\% after MVR; freedom from endocarditis is 100\% after AVR and 99.2\% ± 0.7\% after MVR. No cases of intrinsic structural valve failure were observed.The SBP has shown excellent results in terms of clinical improvement and freedom from valve-related complications, even up to 17 years after AVR and MVR. It therefore seems to be a safe option whenever a mechanical prosthesis is needed.
Single center experience with the Sorin Bicarbon prosthesis: A 17-year clinical follow-up
MILANO, Aldo Domenico;
2014-01-01
Abstract
To evaluate the long-term results of aortic valve replacement (AVR) and mitral valve replacement (MVR) with the Sorin Bicarbon prosthesis (SBP).Five hundred seven patients (306 men, 201 women), mean age 62 ± 10 years (range, 21-86 years), received an SBP between 1994 and 2000; AVR was performed in 344 (67\%) and MVR in 163 (33\%). The main concomitant procedure was coronary artery grafting in 79 patients (16\%). Follow-up was 99\% complete; mean follow-up was 12.7 ± 4.0 years with a cumulative duration of follow-up of 6475 patient-years in the entire group (4348 patient-years for AVR and 2124 patient-years for MVR).Hospital mortality was 2.7\% (AVR, 2.03\%; MVR, 4.3\%). There were 169 late deaths (AVR, 128; MVR, 41). Actuarial survival at 17 years is 49.7\% ± 5.3\% for AVR and 62.0\% ± 6.1\% for MVR. At the last follow-up, 310 survivors (199 AVR, 111 MVR) are in New York Heart Association functional class I or II. At 17 years, actuarial freedom from valve-related deaths, embolism, and bleeding is 89.8\% ± 4.8\%, 85.8\% ± 5.4\%, and 96.2\% ± 1.2\% after AVR, and 91.9\% ± 3.9\%, 96.3\% ± 1.8\%, 95.0\% ± 2.9\% after MVR. Reoperation was required in 5 patients with AVR (thrombosis in 4 and perivalvular leak in 1). Actuarial freedom from reoperation is 98.1\% ± 0.8\% after AVR and 100\% after MVR; freedom from endocarditis is 100\% after AVR and 99.2\% ± 0.7\% after MVR. No cases of intrinsic structural valve failure were observed.The SBP has shown excellent results in terms of clinical improvement and freedom from valve-related complications, even up to 17 years after AVR and MVR. It therefore seems to be a safe option whenever a mechanical prosthesis is needed.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.